600713 南京医药
2024/06 - 中期2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)4.7979.29311.23211.3999.102
总资产报酬率 ROA (%)1.0371.9242.0712.0501.659
投入资产回报率 ROIC (%)1.7583.7884.1603.7213.202

边际利润分析
销售毛利率 (%)6.1666.1836.4906.5096.357
营业利润率 (%)2.0031.8801.8601.8741.698
息税前利润/营业总收入 (%)2.9772.8232.6712.8382.605
净利润/营业总收入 (%)1.4601.3301.4261.3531.180

收益指标分析
经营活动净收益/利润总额(%)104.48996.540114.275104.192106.760
价值变动净收益/利润总额(%)0.1920.877-5.369-10.459-13.709
营业外收支净额/利润总额(%)-0.859-3.003-3.125-0.8160.227

偿债能力分析
流动比率 (X)1.4381.4011.3131.3391.230
速动比率 (X)1.1441.0891.0531.0810.994
资产负债率 (%)76.66374.46478.84879.78179.410
带息债务/全部投入资本 (%)64.52755.94856.49863.03865.396
股东权益/带息债务 (%)51.38773.36471.61852.90548.791
股东权益/负债合计 (%)26.96730.41924.04222.30422.903
利息保障倍数 (X)3.0052.8293.0822.8992.885

营运能力分析
应收账款周转天数 (天)87.00587.57190.10679.33273.976
存货周转天数 (天)41.24741.47839.49836.62337.573